A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
As an early event in the viral life cycle, the entry of enveloped viruses into target cells has received considerable attention. Viral fusion to cellular targets has been studied principally with fusion assays in which cells engineered to express the viral envelope are cultured with the target cells. These assays yield valuable information but do not fully recapitulate all of the variables governing the fusion of actual virions to their cellular targets. The virion membrane and the plasma membrane, for example, differ strikingly in their lipid and protein compositions. Two virion-based fusion assays have been described. One is based on the redistribution of a self-quenching fluorophore, whereas the second depends on photosensitized activation of a hydrophobic probe by a fluorescent lipid loaded into the target membrane. These assays are complex and have not been adapted to study fusion in complex cell populations. We have developed a simple, rapid assay allowing the detection of HIV-1 virion fusion to biologically relevant target cells, including primary CD4(+) T lymphocytes. It is based on the incorporation of beta-lactamase-Vpr chimeric proteins (BlaM-Vpr) into HIV-1 virions and their subsequent delivery into the cytoplasm of target cells as a result of virion fusion. This transfer is then detected by enzymatic cleavage of the CCF2 dye, a fluorescent substrate of beta-lactamase (BlaM), loaded in the target cells. BlaM cleaves the beta-lactam ring in CCF2, changing its fluor…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Nguyen, D. H., & Hildreth, J. E. K. (2000) · Journal of Virology · doi:10.1128/jvi.74.7.3264-3272.2000 · Cited by 788
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5698 · Cited by 751 · cited 1×
“Conversely, no shift to increased blue fluorescence was observed in these CCR5-Jurkat T cells when the culture was preincubated with 250 nM TAK-779, an inhibitor of CCR5-dependent entr”
BackgroundZlokarnik, G., Negulescu, P. A., Knapp, T. E., Mere, L., Burres, N., Feng, L., Whitney, M., Roemer, K., & Tsien, R. Y. (1998) · Science · doi:10.1126/science.279.5347.84 · Cited by 690
Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
Schols, D., Struyf, S., Damme, J. V., Esté, J. A., Henson, G., & Clercq, E. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1383 · Cited by 554 · cited 1×
“Consistent with this color change deriving from the fusion of virions to the target cells, essentially no blue cells were detected in virally infected HeLa-CD4 cells pretreated with 250 nM AMD3100, an inhibitor of CXCR4-dependent viral entr”
BackgroundAloia, R. C., Tian, H., & Jensen, F. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5181 · Cited by 440
Nussbaum, O., Broder, C. C., & Berger, E. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5411-5422.1994 · Cited by 338
Dynamic Disruptions in Nuclear Envelope Architecture and Integrity Induced by HIV-1 Vpr
de Noronha, C. M. C., Sherman, M. P., Lin, H. W., Cavrois, M. V., Moir, R. D., Goldman, R. D., & Greene, W. C. (2001) · Science · doi:10.1126/science.1063957 · Cited by 276 · cited 1×
“1-BlaM into the Hin dIII site of pCMV4-HA-Vpr (ref”
MethodSelf-citationHIV-1 Actively Replicates in Naive CD4+ T Cells Residing within Human Lymphoid Tissues
Eckstein, D. A., Penn, M. L., Korin, Y. D., Scripture-Adams, D. D., Zack, J. A., Kreisberg, J. F., Roederer, M., Sherman, M. P., Chin, P. S., & Goldsmith, M. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00217-5 · Cited by 232
Bridger, G. J., Skerlj, R. T., Thornton, D., Padmanabhan, S., Martellucci, S. A., Henson, G. W., Abrams, M. J., Yamamoto, N., & Vreese, K. D. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00002a019 · Cited by 209
Cytosolic Gag p24 as an Index of Productive Entry of Human Immunodeficiency Virus Type 1
Maréchal, V., Clavel, F., Heard, J. M., & Schwartz, O. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2208-2212.1998 · Cited by 207 · cited 1×
“However, in the absence of appropriate viral receptors in the vesicles, this entry pathway does not lead to productive infectio”
Background
Cited by
Items 101–200 of 490
Astrocytes Resist HIV-1 Fusion but Engulf Infected Macrophage Material
Russell, R. A., Chojnacki, J., Jones, D. M., Johnson, E., Do, T., Eggeling, C., Padilla‐Parra, S., & Sattentau, Q. J. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.01.027 · Cited by 93
“BlaM-Vpr Fusion Assay Fusion was assayed using the GeneBLAzer kit (Life Technologies) as described (Cavrois et al., 2002).”
MethodInfluentialHarmon, B., & Ratner, L. (2008) · Journal of Virology · doi:10.1128/jvi.00424-08 · Cited by 92
“CCR5 cells were pretreated with two different inhibitors of PKA, inhibitory peptide PKA-I(14-22) and chemical inhibitor H89, and the effects were studied in a quantitative Env-dependent cell-cell fusion assay.”
BackgroundMethodMoesin regulates stable microtubule formation and limits retroviral infection in cultured cells
Naghavi, M. H., Valente, S. T., Hatziioannou, T., Santos, K. D. L., Wen, Y., Mott, C., Gundersen, G. G., & Goff, S. P. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601475 · Cited by 91
Shang, L., Yue, L., & Hunter, E. (2008) · Journal of Virology · doi:10.1128/jvi.02666-07 · Cited by 91
Venzke, S., Michel, N., Allespach, I., Fackler, O., & Keppler, O. T. (2006) · Journal of Virology · doi:10.1128/jvi.01556-06 · Cited by 89
“To corroborate our finding that the Nefmediated downregulation of the HIV coreceptor CXCR4 alone can interfere with HIV Env-mediated fusion under more natural conditions, we next adapted a recently developed flow cytometry-based virion fusion assay (12) to study directly the efficiency of viral entry in Nef-expressing…”
BackgroundInfluentialA Post-Transcriptional Feedback Mechanism for Noise Suppression and Fate Stabilization
Hansen, M. M. K., Wen, W. Y., Ingerman, E., Razooky, B. S., Thompson, C. E., Dar, R. D., Chin, C. W., Simpson, M. L., & Weinberger, L. S. (2018) · Cell · doi:10.1016/j.cell.2018.04.005 · Cited by 86
Yu, D., Wang, W., Yoder, A., Spear, M., & Wu, Y. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000633 · Cited by 83
“and we observed an absolute lack of entry signals in HIV-1(VSV-G)-infected resting T cells, using two different entry assays. However, these assays, particularly the BlaM-Vpr-based fusion assay”
MethodMicrobial surface display of glucose dehydrogenase for amperometric glucose biosensor
Liang, B., Li, L., Tang, X., Lang, Q., Wang, H., Li, F., Shi, J., Shen, W., Palchetti, I., Mascini, M., et al. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.01.050 · Cited by 88
Seidel, A., Ye, Y., de Armas, L. R., Soto, M., Yarosh, W., Marcsisin, R. A., Tran, D., Selsted, M. E., & Camerini, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009737 · Cited by 86
“to measure inhibition of HIV-1 entry by HNP-1, HBD-2 and RTD-1”
MethodSuddala, K. C., Lee, C. C., Meraner, P., Marin, M., Markosyan, R. M., Desai, T. M., Cohen, F. S., Brass, A. L., & Melikyan, G. B. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007532 · Cited by 88
Multifaceted Mechanisms of HIV-1 Entry Inhibition by Human α-Defensin
Demirkhanyan, L. H., Marin, M., Padilla‐Parra, S., Zhan, C., Miyauchi, K., Jean-Baptiste, M., Novitskiy, G., Lu, W., & Melikyan, G. B. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.375949 · Cited by 85
“Virus-Cell and Cell-Cell Fusion Assays—HIV-1 fusion with target cells was measured using the BlaM assay based on the transfer of viral core-incorporated enzyme to the cytosol (48), as described previously (34).”
MethodHuman Immunodeficiency Virus Fusion to Dendritic Cells Declines as Cells Mature
Cavrois, M., Neidleman, J., Kreisberg, J. F., Fenard, D., Callebaut, C., & Greene, W. C. (2006) · Journal of Virology · doi:10.1128/jvi.80.4.1992-1999.2006 · Cited by 76
“Importantly, the virion-based fusion assay selectively detects HIV-1 virions entering cells by fusion but not by endocytosis (11).”
BackgroundMethodInfluentialSelf-citationDopamine Receptor Activation Increases HIV Entry into Primary Human Macrophages
Gaskill, P. J., Yano, H., Kalpana, G. V., Javitch, J. A., & Berman, J. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108232 · Cited by 86
“contained within the infecting virus cleaves the lactam ring and separates the fluorophores [45].”
BackgroundLi, Q., Li, W., Yin, W., Guo, J., Zhang, Z., Zeng, D., Zhang, X., Wu, Y., Zhang, X., & Cui, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b00275 · Cited by 84
Aminoquinoline Surfen Inhibits the Action of SEVI (Semen-derived Enhancer of Viral Infection)
Roan, N. R., Sowinski, S., Münch, J., Kirchhoff, F., & Greene, W. C. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.066167 · Cited by 81
Self-citationHeffner, G. C., Bonner, M., Christiansen, L., Pierciey, F. J., Campbell, D., Smurnyy, Y., Zhang, W., Hamel, A., Shaw, S., Lewis, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.09.025 · Cited by 72
“PGE2 Does Not Promote Viral Entry To determine at which step in the LVV transduction cycle PGE2 exerts an effect, we performed a b-lactamase (BlaM) assay using VPRBlaM-loaded LVV particles that readout viral entry versus later stage of the LVV integration process.(15) We did not observe an increase in BlaM cells when…”
MethodHerold, N., Anders‐Össwein, M., Glass, B., Eckhardt, M., Müller, B., & Kräusslich, H. (2014) · Journal of Virology · doi:10.1128/jvi.01543-14 · Cited by 90
“Effective inhibition of coreceptor binding was validated using a -lactamase reporter-based HIV-1 fusion assay (51), revealing a complete block of fusion for viruses carrying a mutation in the coreceptor binding site or with pharmacological inhibition of coreceptor binding (data not shown).”
MethodArfi, V., Rivière, L., Jarrosson, L., Goujon, C., Rigal, D., Darlix, J., & Cimarelli, A. (2008) · Journal of Virology · doi:10.1128/jvi.02321-07 · Cited by 84
“Next, viral entry was examined by using a Vpr-BLAM assay that measures the cytosolic presence of Vpr-BLAM after virusto-cell fusion (3).”
BackgroundMethodInfluentialRichards, A. L., Sollars, P. J., Pitts, J. D., Stults, A. M., Heldwein, E. E. Z., Pickard, G. E., & Smith, G. A. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006741 · Cited by 83
“To specifically monitor fusion-based virus entry into axons, an enzyme-based assay was developed based on an approach that was used to monitor HIV fusion with T lymphocytes [51].”
Host MicroRNAs-221 and -222 Inhibit HIV-1 Entry in Macrophages by Targeting the CD4 Viral Receptor
Lodge, R., Barbosa, J. A. F., Lombard‐Vadnais, F., Gilmore, J. C., Deshière, A., Gosselin, A., Salinas, T. R. W., Bego, M. G., Power, C., Routy, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.030 · Cited by 77
“The use of the Blam-Vpr fusion-specific assay (Cavrois et al., 2002), which does not rely on virus post fusion steps, allowed us to show that part of the blocks to HIV-1 infection induced by TNF-a are taking place at the entry stage (Figure 5D), in agreement with previous observations (Herbein et…”
MethodResultInfluentialHulseberg, C. E., Fénéant, L., Wijs, K. S.-D., & White, J. M. (2018) · mBio · doi:10.1128/mbio.01818-17 · Cited by 76
Andrade, V. M., Mavian, C. N., Babič, D. Z., Cordeiro, T. I., Sharkey, M. E., Barrios, L., Brander, C., Martínez‐Picado, J., Dalmau, J., Llano, A., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1917034117 · Cited by 77
“A modified fusion assay, originally developed to measure HIV-1 fusogenicity on CD4+ T cells (14), was used to assess the fusogenic capacities of the recombinant viruses on macrophages.”
MethodFenard, D., Ingrao, D., Seye, A. K., Buisset, J., Genries, S., Martin, S., Kichler, A., & Galy, A. H. M. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.17 · Cited by 75
Adding new dimensions: towards an integrative understanding of HIV-1 spread
Fackler, O., Murooka, T. T., Imle, A., & Mempel, T. R. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3309 · Cited by 76
Cannabinoid Receptor 2-Mediated Attenuation of CXCR4-Tropic HIV Infection in Primary CD4+ T Cells
Costantino, C. M., Gupta, A., Yewdall, A. W., Dale, B. M., Devi, L. A., & Chen, B. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033961 · Cited by 77
Mass Cytometric Analysis of HIV Entry, Replication, and Remodeling in Tissue CD4+ T Cells
Cavrois, M., Banerjee, T., Mukherjee, G., Raman, N., Hussien, R., Rodriguez, B. A., Vasquez, J., Spitzer, M. H., Lazarus, N. H., Jones, J. J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.087 · Cited by 75
“The HIV fusion assay detects transfer of a BlaM-Vpr chimeric protein, co-packaged into virus particles, from the virion into the cytoplasm of target cells, and thereby allows measurement of HIV entry independent of viral gene expression (Cavrois et al., 2002).”
BackgroundSelf-citationAn enzymatic virus-like particle assay for sensitive detection of virus entry
Tscherne, D. M., Manicassamy, B., & García‐Sastre, A. (2009) · Journal of Virological Methods · doi:10.1016/j.jviromet.2009.10.020 · Cited by 70
Lucera, M. B., Tilton, C. A., Mao, H., Dobrowolski, C. N., Tabler, C. O., Haqqani, A. A., Karn, J., & Tilton, J. C. (2014) · Journal of Virology · doi:10.1128/jvi.00320-14 · Cited by 77
“To investigate how vorinostat promotes susceptibility to infec- HIVFusionCombination Reporter Virus System U nc le av ed C C F2 (5 20 n m ) Cleaved CCF2 (447 nm) HIV+ A C Fusion C C R 7 CD45RO NL4-3 Core ΔEnv EGFP Env bla-Vpr TN TCM TTE TEM 0.04 66.2 B 10806 jvi.asm.org Journal of Virology tion, we measured its effect…”
BackgroundInfluentialHIV-1 and HTLV-1 Transmission Modes: Mechanisms and Importance for Virus Spread
Kalinichenko, S., Komkov, D., & Mazurov, D. (2022) · Viruses · doi:10.3390/v14010152 · Cited by 68
“BlaM analysis allows the detection and quantification of the transmission of viral particles by fluorescence microscopy, flow cytometry, or UV photometry [27].”
MethodMiyauchi, K., Kozlov, M. M., & Melikyan, G. B. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000585 · Cited by 68
“In order to directly monitor HIV-1 fusion with target cells, we measured the cytosolic activity of the beta-lactamase-Vpr (BlaM-Vpr) chimera packaged into the viral core”
In vitro methods for testing antiviral drugs
Rumlová, M., & Ruml, T. (2017) · Biotechnology Advances · doi:10.1016/j.biotechadv.2017.12.016 · Cited by 72
“The fluorescence shift corresponds to the fusion efficacy and is measurable by fluorescence microscopy, flow cytometry, or fluorometric plate reader (Cavrois et al., 2002; Cavrois et al., 2004 Cavrois et al., , 2014 .”
BackgroundBouvet, M., Voigt, S., Tagawa, T., Albanese, M., Chen, Y. A., Chen, Y., Fachko, D. N., Pich, D., Göbel, C., Skalsky, R. L., et al. (2021) · mBio · doi:10.1128/mbio.03440-20 · Cited by 67
“Upon infection the chimeric protein is delivered into the cytoplasm of HIV target cells as a result of virion fusion (Cavrois et al., 2002; Cavrois et al., 2014; Jones and Padilla-Parra, 2016).”
BackgroundMethodInfluentialSARS-CoV-2 ORF7a potently inhibits the antiviral effect of the host factor SERINC5
Timilsina, U., Umthong, S., Ivey, E. B., Waxman, B., & Stavrou, S. (2022) · Nature Communications · doi:10.1038/s41467-022-30609-9 · Cited by 69
Zaire Ebola virus entry into human dendritic cells is insensitive to cathepsin L inhibition
Martinez, O., Johnson, J. C., Manicassamy, B., Rong, L., Olinger, G. G., Hensley, L. E., & Basler, C. F. (2009) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01385.x · Cited by 67
“…of the b-lactamase tag in the VLPs can be detected using a fluorescence microscope, fluorescence plate reader or flow cytometry to measure VLP entry within 4 h of infection and, unlike pseudotyped virus systems, does not require postentry steps in the virus replication cycle (Cavrois et al., 2002).”
BackgroundMonel, B., Beaumont, E., Vendrame, D., Schwartz, O., Brand, D., & Mammano, F. (2012) · Journal of Virology · doi:10.1128/jvi.06478-11 · Cited by 64
“To this end, we adapted the VprLam protocol (12, 60) to the situation in which HIV is transmitted from cell to cell (10).”
MethodDavis, M. R., Jiang, J., Zhou, J., Freed, E. O., & Aiken, C. (2006) · Journal of Virology · doi:10.1128/jvi.80.5.2405-2417.2006 · Cited by 63
“Furthermore, the signal is inhibited by coreceptor antagonists and the HIV-1 inhibitor T-20 (8, 79).”
BackgroundMethodBonar, M. M., & Tilton, J. C. (2017) · Virology · doi:10.1016/j.virol.2017.02.016 · Cited by 70
“Upon fusion with host cells, these viruses release active β-lactamase that cleaves the FRET substrate CCF2, generating a colorimetric change to the cells that can be analyzed by flow cytometry (Cavrois et al., 2002).”
BackgroundMarkosyan, R. M., Cohen, F. S., & Melikyan, G. B. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-06-0496 · Cited by 65
“For example, one can introduce -lactamase into the viral core (Cavrois et al., 2002; Tobiume et al., 2003; Barnard et al., 2004; Wyma et al., 2004; Daecke et al., 2005) or associate luciferase with the viral envelope proteins (Kolokoltsov and Davey, 2004) and quantify fusion from measures of these enzymatic activities…”
BackgroundMorrow, M. P., Grant, A., Mujawar, Z., Dubrovsky, L., Pushkarsky, T., Kiselyeva, Y., Jennelle, L. T., Mukhamedova, N., Remaley, A. T., Kashanchi, F., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.065029 · Cited by 66
“Since the effect of cholesterol depletion is expected to manifest at the step of virus-cell fusion, we used the FRET-based HIV-1 virion fusion assay (Cavrois et al., 2002) to measure fusion of viruses produced in HEK 293T cells in the presence or absence of ABCA1.”
MethodLiu, Y., Fu, Y., Wang, Q., Li, M., Zhou, Z., Dabbagh, D., Fu, C., Zhang, H., Li, S., Zhang, T., et al. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0372-2 · Cited by 67
Hyperthermia Stimulates HIV-1 Replication
Roesch, F., Méziane, O., Kula, A., Nisole, S., Porrot, F., Anderson, I., Mammano, F., Fassati, A., Marcello, A., Benkirane, M., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002792 · Cited by 65
“. To quantify HIV-1 entry in Jurkat cells, we used a virion fusion assay, which allows to discriminate cytoplasmic access of viral cores from endosomal capture”
MethodMucosal stromal fibroblasts markedly enhance HIV infection of CD4+ T cells
Neidleman, J. A., Chen, J. C., Kohgadai, N., Müller, J. A., Laustsen, A., Thavachelvam, K., Jang, K. S., Stürzel, C. M., Jones, J. J., Ochsenbauer, C., et al. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006163 · Cited by 66
Self-citationHIV-1 virion fusion assay: uncoating not required and no effect of Nef on fusion
Cavrois, M., Neidleman, J. A., Yonemoto, W. M., Fenard, D., & Greene, W. C. (2004) · Virology · doi:10.1016/j.virol.2004.07.015 · Cited by 64
“To test whether Nef alters the fusion of HIV-1 virions, we developed a virion-based fusion assay (Cavrois et al., 2002, 2004).”
MethodInfluentialSelf-citationLabeling of Multiple HIV-1 Proteins with the Biarsenical-Tetracysteine System
Pereira, C. F., Ellenberg, P. C., Jones, K. L., Fernandez, T. L., Smyth, R. P., Hawkes, D. J., Hijnen, M., Vivet‐Boudou, V., Marquet, R., Johnson, I. D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017016 · Cited by 63
“The capacity of HIV to enter lymphoid cells was assessed by measuring the cytosolic activity of viral-core-associated b-lactamase [20].”
Entry and replication of recombinant hepatitis C viruses in cell culture
Vièyres, G., & Pietschmann, T. (2012) · Methods · doi:10.1016/j.ymeth.2012.09.005 · Cited by 69
PSGL-1 restricts HIV-1 infectivity by blocking virus particle attachment to target cells
Fu, Y., He, S., Waheed, A. A., Dabbagh, D., Zhou, Z., Trinité, B., Wang, Z., Yu, J., Wang, D., Li, F., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916054117 · Cited by 65
“S10) inhibit virus entry, we performed a beta-lactamase–based virus entry assay (26) (Fig.”
Roan, N. R., Liu, H., Usmani, S. M., Neidleman, J. A., Müller, J. A., Avila-Herrera, A., Gawanbacht, A., Zirafi, O., Chu, S., Dong, M., et al. (2014) · Journal of Virology · doi:10.1128/jvi.00269-14 · Cited by 62
“Viral fusion was assessed by measuring the shift in fluorescence in target cells 427 pre-loaded with the fluorescent compound CCF2 as previously described (19).”
Self-citationBam, R. A., Hansen, D., Irrinki, A., Mulato, A. S., Jones, G. S., Hesselgesser, J., Frey, C. R., Cihlář, T., & Yant, S. R. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01369-16 · Cited by 66
“Target cells were loaded with CCF2 substrate dye, and CD3 CD4 CD8 cells containing virus were enumerated by flow cytometry to detect the cleaved CCF2 dye after 16 h of incubation (Fig.”
BackgroundMethodInfluentialThe V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity
Wang, Y., Pan, Q., Ding, S., Wang, Z., Yu, J., Finzi, A., Liu, S.-L., & Liang, C. (2017) · Journal of Virology · doi:10.1128/jvi.02441-16 · Cited by 56
“A BlaM-Vpr assay was performed to measure HIV-1 entry (65, 66).”
MethodKoedel, Y., Eissmann, K., Wend, H., Fleckenstein, B., & Reil, H. (2011) · Journal of Virology · doi:10.1128/jvi.02366-10 · Cited by 60
“The virion-based fusion assay was performed essentially as described elsewhere (6).”
MethodAhi, Y. S., Zhang, S., Thappeta, Y., Denman, A., Feizpour, A., Gummuluru, S., Reinhard, B. M., Muriaux, D. M., Fivash, M. J., & Rein, A. R. (2016) · mBio · doi:10.1128/mbio.01985-16 · Cited by 66
“(Many studies on HIV-1 entry have used the Vpr-BLaM assay [33, 34], but this requires Vpr or an equivalent protein, which is not available in MLV.”
MethodIdentification of a CCR5-Expressing T Cell Subset That Is Resistant to R5-Tropic HIV Infection
Oswald-Richter, K. A., Grill, S. M., Leelawong, M., Tseng, M., Kalams, S. A., Hulgan, T., Haas, D. W., & Unutmaz, D. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030058 · Cited by 60
“For this experiment, we employed a recently developed reporter assay to quantify HIV particle entry [25].”
MethodHerpesviruses assimilate kinesin to produce motorized viral particles
Pegg, C. E., Zaichick, S., Bomba-Warczak, E. K., Jovasevic, V., Kim, D., Kharkwal, H., Wilson, D. W., Walsh, D., Sollars, P. J., Pickard, G. E., et al. (2021) · Nature · doi:10.1038/s41586-021-04106-w · Cited by 61
Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection
Lee, D. Y. W., Lin, X., Paskaleva, E. E., Liu, Y., Puttamadappa, S. S., Thornber, C., Drake, J. R., Habulin, M., Shekhtman, A. G., & Canki, M. (2009) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2009.0019 · Cited by 59
“Greene,(26) and HIV-1 virions containing the BlaM-Vpr chimera were produced by cotransfection of 293T cells with pNL4-3 proviral DNA (60 mg), pCMV-BlaM-Vpr (20 mg), and pAdVAntage vectors (10mg) (Invitrogen), as previously described.(26) After 48 h at 378C, the virus-containing supernatant was centrifuged at low speed…”
Reporter gene assay for membrane fusion of extracellular vesicles
Somiya, M., & Kuroda, S. (2021) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12171 · Cited by 61
Inhibition of HIV-1 Replication by Amphotericin B Methyl Ester
Waheed, A. A., Ablan, S. D., Mankowski, M. K., Cummins, J. E., Ptak, R. G., Schaffner, C. P., & Freed, E. O. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603609200 · Cited by 59
Low CCR5 expression protects HIV-specific CD4+ T cells of elite controllers from viral entry
Claireaux, M. A. F., Robinot, R., Kervevan, J., Patgaonkar, M. S., Staropoli, I., Brelot, A., Nouël, A., Gellenoncourt, S., Tang, X., Hery, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28130-0 · Cited by 61
Characterizing the Anti-HIV Activity of Papuamide A
Andjelic, C. D., Planelles, V., & Barrows, L. R. (2008) · Marine Drugs · doi:10.3390/md20080027 · Cited by 57
“The following plasmids have been described elsewhere, pMM310 [21],pDHIV-3 [27], pHCMV-VSVG [34], pLET-JRFL [53], and pLET-LAI [53, 54].”
Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon
Akiyama, H., Ramirez, N.-G. P., Gibson, G. A., Kline, C. E., Watkins, S. C., Ambrose, Z., & Gummuluru, S. (2017) · Journal of Virology · doi:10.1128/jvi.00972-17 · Cited by 57
“For the virus fusion assay described below, HEK293T cells were cotransfected with HIV-1 infectious constructs with pMM310, a plasmid encoding BlaM-Vpr fusion protein (43), or with HIV-1 LaiΔenv-luc, an Env expression construct, and pMM310.”
MethodThe tyrosine kinase inhibitor genistein blocks HIV-1 infection in primary human macrophages
Stantchev, T. S., Markovic, I., Telford, W. G., Clouse, K. A., & Broder, C. C. (2006) · Virus Research · doi:10.1016/j.virusres.2006.09.004 · Cited by 60
“However, there are concerns that cell-fusion assays may not reflect all the variables governing the fusion of actual virions with their target cells, due to the significant differences in the composition of virus and plasma membranes (Cavrois et al., 2002).”
BackgroundMethodInfluentialThe CARD8 inflammasome dictates HIV/SIV pathogenesis and disease progression
Wang, Q., Clark, K. M., Tiwari, R., Raju, N., Tharp, G. K., Rogers, J., Harris, R. A., Raveendran, M., Bosinger, S. E., Burdo, T. H., et al. (2024) · Cell · doi:10.1016/j.cell.2024.01.048 · Cited by 56
Interferon-inducible LY6E Protein Promotes HIV-1 Infection
Yu, J., Liang, C., & Liu, S.-L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.755819 · Cited by 54
“Virion-Cell Fusion—The BlaM-Vpr-based HIV-1 entry assay was used for virion-cell fusion as described previously (48).”
MethodRoque, A. C. A., Taipa, M. Â., & Lowe, C. R. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.733 · Cited by 56
“…monoclonal antibodies and their genetically engineered derivatives are biomolecules with unquestionable value as therapeutic (Reichert, 2001; van Dijk and van de Winkel, 2001), diagnostic (Cavrois et al., 2002; Safar et al., 2002) and purification (Blank et al., 2002; Fong et al., 2002) tools.”
BackgroundRuffin, N., Gea‐Mallorquí, E., Brouiller, F., Jouve, M. J., Silvin, A., See, P., Dutertre, C., Ginhoux, F., & Benaroch, P. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911007116 · Cited by 58
UPF1 Is Crucial for the Infectivity of Human Immunodeficiency Virus Type 1 Progeny Virions
Serquiña, A., Das, S. R., Popova, E. N., Ojelabi, O., Roy, C. K., & Göttlinger, H. G. (2013) · Journal of Virology · doi:10.1128/jvi.00925-13 · Cited by 61
“To determine whether UPF1R865A affected the ability of progeny virions to enter target cells, we used a previously described fusion assay that is based on the incorporation of a chimeric -lactamase–Vpr (BlaM-Vpr) protein into progeny virions (38).”
BackgroundMethodCaveolin-1 mediated uptake via langerin restricts HIV-1 infection in human Langerhans cells
Berg, L., Ribeiro, C. M. S., Willems, E., de Witte, L. D., Fluitsma, D. M., Tigchelaar, W., Everts, V. E., & Geijtenbeek, T. B. H. (2014) · Retrovirology · doi:10.1186/s12977-014-0123-7 · Cited by 54
Jha, N. K., Latinovic, O., Martin, E. W., Novitskiy, G., Marin, M., Miyauchi, K., Naughton, J., Young, J. A. T., & Melikyan, G. B. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001260 · Cited by 56
“The EcpH quenching assay reports the EnvA-mediated virus delivery into acidic compartments, but does not directly measure the step of virus engulfment by an endosome. Also, EcpH quenching measures the bulk uptake, irrespective of whether or not it leads to EnvA-driven fusion with an endosome. To assess the rates of pr…”
MethodGoffinet, C., Allespach, I., & Keppler, O. T. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607414104 · Cited by 52
Swartz, T. H., Esposito, A. M., Durham, N. D., Hartmann, B., & Chen, B. K. (2014) · Journal of Virology · doi:10.1128/jvi.01158-14 · Cited by 52
“virions was measured as described previously (28).”
Bhakta, S. J., Shang, L., Prince, J. L., Claiborne, D. T., & Hunter, E. (2011) · Retrovirology · doi:10.1186/1742-4690-8-37 · Cited by 53
“In order to further define the defect in entry, we utilized the b-lactamase virus-cell fusion assay described previously [ 57-60 ].”
Methodα-Complementation assay for HIV envelope glycoprotein-mediated fusion
Holland, A. U., Münk, C., Lucero, G. R., Nguyen, L. D., & Landau, N. R. (2004) · Virology · doi:10.1016/j.virol.2003.11.012 · Cited by 53
“These include single replication cycle viruses that contain a reporter gene (Connor et al., 1995), virions loaded with h-lactamase (Cavrois et al., 2002), and cell–cell fusion assays (Lineberger et al., 2002; Nussbaum et al., 1994).”
BackgroundMethodGilbertson, B. P., Zheng, T., Gerber, M., Printz-Schweigert, A., Ong, C., Marquet, R., Isel, C., Rockman, S. P., & Brown, L. E. (2016) · Viruses · doi:10.3390/v8080238 · Cited by 50
Volotskova, O., Dubrovsky, L., Keidar, M., & Bukrinsky, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0165322 · Cited by 50
Soluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases
Cocchi, F., DeVico, A. L., Lu, W., Popovič, M., Latinovic, O., Sajadi, M. M., Redfield, R. R., Lafferty, M. K., Galli, M., Demo, A. G., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202240109 · Cited by 49
“We used a BlaM (β-lactamase) entry assay (34) to detect and measure virus cell fusion in PBMCs.”
Methodvan Wilgenburg, B., Moore, M. D., James, W., & Cowley, S. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086071 · Cited by 56
“, measures the fusion of HIV-1 envelope with a cell-limiting membrane [50].”
BackgroundDesai, T. M., Marin, M., Sood, C., Shi, J., Nawaz, F., Aiken, C., & Melikyan, G. B. (2015) · Retrovirology · doi:10.1186/s12977-015-0215-z · Cited by 50
“This strategy has been successfully used to incorporate integrase and reverse transcriptase, as well as cyclophilin A and β-lactamase, into virions [13–16].”
MethodMarmé, N., Knemeyer, J., Wolfrum, J., & Sauer, M. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200453835 · Cited by 49
Scholz, I., Arvidson, B., Huseby, D. L., & Barklis, E. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1470-1479.2005 · Cited by 49
“Cells were analyzed as described previously (8, 32, 47) on a”
BackgroundMethodInfluentialAlbanese, M., Ruhle, A., Mittermaier, J., Mejías‐Pérez, E., Gapp, M., Linder, A., Schmacke, N. A., Hofmann, K., Hennrich, A. A., Levy, D. N., et al. (2021) · Nature Methods · doi:10.1038/s41592-021-01328-8 · Cited by 52
Landowski, M., Dabundo, J., Liu, Q., Nicola, A. V., & Aguilar, H. C. (2014) · Journal of Virology · doi:10.1128/jvi.01632-14 · Cited by 48
“Upon reaction with La, CCF2 is further hydrolyzed, causing a disruption in resonant energy transfer and a change from green to blue fluorescence when excited by light (28, 29).”
BackgroundMa, T., Luo, X., George, A. F., Mukherjee, G., Sen, N., Spitzer, T., Giudice, L. C., Greene, W. C., & Roan, N. R. (2020) · eLife · doi:10.7554/elife.55487 · Cited by 49
“Implementation of the FACS-based virion fusion assay – which identifies cells that HIV has entered (Cavrois et al., 2002) – on endocervical specimens revealed preferential entry of HIV into cells with higher levels of the CCR5 co-receptor and the activation/T resident memory (Trm) marker CD69 (Joag et al.”
BackgroundSelf-citationStudying HCV Cell Entry with HCV Pseudoparticles (HCVpp)
Bartosch, B., & Cosset, F. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-394-3_21 · Cited by 48
MicroRNA-Mediated Restriction of HIV-1 in Resting CD4+ T Cells and Monocytes
Chiang, K., & Rice, A. P. (2012) · Viruses · doi:10.3390/v4091390 · Cited by 50
“Pseudotyped virus expressing Vpr-beta-lactamase (BLAM) also showed a defect in entry, as measured by decreased cleavage of intracellular CCF2 dye [55,56].”
BackgroundDiscovery of Novel Small-Molecule Inhibitors of LIM Domain Kinase for Inhibiting HIV-1
Yi, F., Guo, J., Dabbagh, D., Spear, M., He, S., Kehn‐Hall, K., Fontenot, J., Yin, Y. B., Bibian, M., Park, C. M., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02418-16 · Cited by 47
“as measured by infection with HIV-1(Vpr- -lactamase) (46) (Fig.”
BackgroundMethodA SNAP-Tagged Derivative of HIV-1—A Versatile Tool to Study Virus-Cell Interactions
Eckhardt, M., Anders‐Össwein, M., Muranyi, W., Heilemann, M., Krijnse‐Locker, J., & Müller, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022007 · Cited by 46
“). In order to determine the efficiency of cytoplasmatic entry, we made use of the so-called beta-lactamase virion fusion assay (BlaM assay) for HIV cell fusion”
Fluorescence Resonance Energy Transfer-Based HIV-1 Virion Fusion Assay
Cavrois, M., Neidleman, J. A., Bigos, M., & Greene, W. C. (2004) · Humana Press eBooks · doi:10.1385/1-59259-773-4:333 · Cited by 46
“The methods described in the following subheadings outline: (1) the production of HIV-1 virions containing BlaM-Vpr, (2) the FRET-based HIV-1 virion fusion assay, and (3) the analysis by flow cytometry.”
MethodSelf-citationOn the steps of cell-to-cell HIV transmission between CD4 T cells
Puigdomènech, I., Massanella, M., Cabrera, C., Clotet, B., & Blanco, J. (2009) · Retrovirology · doi:10.1186/1742-4690-6-89 · Cited by 47
“Given the relevance of primary cells, this limitation can be overcome by monitoring early events of the HIV life cycle such as the synthesis of proviral DNA [14], or the access of HIV cores to the cytoplasm using fluorescent techniques [26].”
BackgroundHuman Immunodeficiency Virus Type 1 Nef Incorporation into Virions Does Not Increase Infectivity
Laguette, N., Bénichou, S., & Basmaciogullari, S. (2008) · Journal of Virology · doi:10.1128/jvi.01633-08 · Cited by 48
“In addition, various proteins fused to Vpr were shown to be efficiently incorporated into HIV-1 particles while retaining their original properties (17, 32, 57, 93, 94).”
Backgroundβ-Lactamase: An Ideal Reporter System for Monitoring Gene Expression in live Eukaryotic Cells
Qureshi, S. A. (2007) · BioTechniques · doi:10.2144/000112292 · Cited by 45
“This biosensor has also been used for studying protein folding (16), adaptive and targeted gene evolution (17,18), protease activity (19), gene trapping (20,21), fusion of human immunodeficiency virus (HIV) virions to primary CD4+ T lymphocytes (22,23), RNA splicing (24), and protein-protein interactions by fragment c…”
MethodYang, R., & Aiken, C. (2007) · Journal of Virology · doi:10.1128/jvi.02634-06 · Cited by 46
“To further define the defect associated with the T54A mutation, we first analyzed entry of the mutant particles using the -lactamase-based reporter fusion assay (10).”
MethodThe Ataxia Telangiectasia-Mutated and Rad3-Related Protein Is Dispensable for Retroviral Integration
DeHart, J. L., Andersen, J. L., Zimmerman, E. S., Ardon, O., An, D. S., Blackett, J., Kim, B., & Planelles, V. (2005) · Journal of Virology · doi:10.1128/jvi.79.3.1389-1396.2005 · Cited by 43
“Although integration-defective vectors cannot be titrated via expression of the reporter gene, they are competent for viral fusion and entry (9, 20).”
BackgroundHIV-1 mutates to evade IFITM1 restriction
Ding, S., Pan, Q., Liu, S., & Liang, C. (2014) · Virology · doi:10.1016/j.virol.2014.01.020 · Cited by 44
“HIV-1 virion fusion assay The experiment was performed as described previously (Cavrois et al., 2002; Lu et al., 2011).”
MethodCobbin, J. C. A., Ong, C., Verity, E. E., Gilbertson, B. P., Rockman, S. P., & Brown, L. E. (2014) · Journal of Virology · doi:10.1128/jvi.01022-14 · Cited by 44
“HA and PB1 PR8 HA PR8 PB1 34 (92) 25 (71) 21 (68) 80 (77 13) PR8 HA Udorn PB1 1 (3) 5 (14) 4 (13) 10 (10 6) Udorn HA PR8 PB1 2 (5) 5 (14) 5 (16) 12 (12 6) Udorn HA Udorn PB1 0 (0) 0 (0) 1 (3) 1 (1 2)”
MethodTeriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity
Ambrosius, B., Faissner, S., Guse, K., von Lehe, M., Grunwald, T., Gold, R., Grewe, B., & Chan, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0829-2 · Cited by 50
Hsiao, F., Frouard, J., Gramatica, A., Xie, G., Telwatte, S., Lee, G. Q., Roychoudhury, P., Schwarzer, R., Luo, X., Yukl, S. A., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008450 · Cited by 48
“By comparing cells capable of fusing to CCR5-tropic HIV through use of the virion fusion assay [12] to those which HIV was capable of productively infecting as revealed by expression of an LTR-driven reporter gene, we were able to determine which subsets harboring HIV virions went on to become…”
Self-citationSpear, M., Guo, J., Turner, A., Yu, D., Wang, W., Meltzer, B., He, S., Hu, X., Shang, H., Kuhn, J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.492132 · Cited by 49
“Viral Entry Assays—The BlaM-Vpr-based viral entry assay was performed as previously described (7, 20).”
MethodDistinct Requirements for HIV-Cell Fusion and HIV-mediated Cell-Cell Fusion
Kondo, N., Marin, M., Kim, J. H., Desai, T. M., & Melikyan, G. B. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.623181 · Cited by 44
“Following the FFWO measurement in cells loaded with a cell-permeable Renilla luciferase substrate, the extent of HIV-cell fusion was determined in the same sample using the -lactamase (BlaM) assay, as described previously (13, 45).”
MethodRealization of $beta;-lactamase as a versatile fluorogenic reporter
Campbell, R. E. (2004) · Trends in biotechnology · doi:10.1016/s0167-7799(04)00086-1 · Cited by 44
Agosto, L. M., Yu, J. J., Liszewski, M. K., Baytop, C., Korokhov, N., Humeau, L. M., & O'Doherty, U. (2009) · Journal of Virology · doi:10.1128/jvi.00220-09 · Cited by 43
“To test this, we employed a BlaM-Vpr virus-to-cell fusion assay (7, 54).”
MethodCell-type specific requirements for thiol/disulfide exchange during HIV-1 entry and infection
Stantchev, T. S., Paciga, M., Lankford, C. S. R., Schwartzkopff, F., Broder, C. C., & Clouse, K. A. (2012) · Retrovirology · doi:10.1186/1742-4690-9-97 · Cited by 43
Metadata
- Authors
- Cavrois, M., de Noronha, C., & Greene, W. C.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Greene, Warner C.
- Venue
- Nature Biotechnology
- Published
- 2002-09-30
- Volume
- 20
- Issue
- 11
- Pages
- 1151-1154
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2029379203
- Cited by
- 475
- References
- 16
- Citations by year
- 2026: 13 · 2025: 11 · 2024: 12 · 2023: 9 · 2022: 19 · 2021: 24 · 2020: 22 · 2019: 25 · 2018: 20 · 2017: 31 · 2016: 16 · 2015: 27 · 2014: 28 · 2013: 22 · 2012: 31
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P01 HD40543, P01HD040543)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1, viral entry, fluorescent substrate, HIV-1 envelope
- MeSH terms
- Cell Fusion, Humans, Immunoenzyme Techniques, Membrane Fusion, Sensitivity and Specificity, T-Lymphocytes, Tumor Cells, Cultured, Viral Fusion Proteins, Virion, Reproducibility of Results, HIV-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.